Psychedelic Stock Picks — Investing in the psychedelic medicine market
Featured
Psychedelic Stocks: Start With Evidence, Not a Story
By Psychedelic Stock Picks Editorial Team · November 8, 2026
Read article 1 / 5
News & insights
Insight
Sector Funds and Concentration Risk: Look Past the Label
By Psychedelic Stock Picks Editorial Team · November 8, 2026
News
FDA’s 2023 Psychedelic Guidance: Development, Not Approval
By Psychedelic Stock Picks Editorial Team
News
The 2022 Psilocybin Depression Trial: Reading Beyond the Headline
By Psychedelic Stock Picks Editorial Team
News
A 2023 JAMA Psilocybin Trial: Outcomes, Support, and Limits
By Psychedelic Stock Picks Editorial Team
Editor's picks
Editor's pick
Psychedelic Stocks: Start With Evidence, Not a Story
By Psychedelic Stock Picks Editorial TeamNovember 8, 2026
Editor's pick
Cash Runway and Dilution: Reading a Biotech Balance Sheet
By Psychedelic Stock Picks Editorial TeamNovember 8, 2026
Editor's pick
Phase 1, 2, and 3: What Trial Labels Mean for Investors
By Psychedelic Stock Picks Editorial TeamNovember 8, 2026
Editor's pick
SEC Filings: A Document-First Guide to Biotech Research
By Psychedelic Stock Picks Editorial TeamNovember 8, 2026
Editor's pick
Sector Funds and Concentration Risk: Look Past the Label
By Psychedelic Stock Picks Editorial TeamNovember 8, 2026
Latest headlines
The big picture
FDA’s 2023 Psychedelic Guidance: Development, Not Approval
November 8, 2026
Read the full storyLatest News
FDA’s 2023 Psychedelic Guidance: Development, Not Approval
November 8, 2026
The 2022 Psilocybin Depression Trial: Reading Beyond the Headline
November 8, 2026
A 2023 JAMA Psilocybin Trial: Outcomes, Support, and Limits
November 8, 2026
The 2023 MDMA-Assisted PTSD Trial: What Phase 3 Did Test
November 8, 2026
ClinicalTrials.gov: Check the Record Before Sharing a Catalyst
November 8, 2026
Latest Insights
Psychedelic Stocks: Start With Evidence, Not a Story
Psychedelic Stock Picks Editorial Team · November 8, 2026